Celldex Therapeutics Inc (CLDX)

3.75
0.04 1.10
NASDAQ : Health Care
Prev Close 3.79
Open 3.85
Day Low/High 3.72 / 3.88
52 Wk Low/High 2.96 / 25.60
Volume 403.33K
Avg Volume 2.47M
Exchange NASDAQ
Shares Outstanding 101.25M
Market Cap 359.43M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Investors considering a purchase of Celldex Therapeutics, Inc. shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

--Conference call to be held at 4:30 p.m. Eastern Time today--

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Celldex Reports Second Quarter 2016 Results

Celldex Reports Second Quarter 2016 Results

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Antibody-drug conjugate directed to TIM-1, a novel target upregulated in several cancers

Celldex Therapeutics (CLDX) In A Perilous Reversal

Celldex Therapeutics (CLDX) In A Perilous Reversal

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

CDX-301's utility as a dendritic cell growth factor in combination therapy established

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting.

Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Great Breadth Fails to Counter Boring Market

This, despite a rare 10-point jump in bulls in the Investors Intelligence readings, which usually occurs in bear markets.

6 Breakout Stocks Under $10 Set to Soar

6 Breakout Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Investors eyeing a purchase of Celldex Therapeutics, Inc. shares, but tentative about paying the going market price of $4.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Weak On High Volume

Celldex Therapeutics (CLDX) Weak On High Volume

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate